바이오테크 보도자료
-
- Sodium Lactate Market Latest Trends, Demand, Growth, Opportunities & Outlook Till 2031: Future Market Insights
- Sodium lactate market revenue totaled US$ 158.7 Mn for 2021, according to a study by Future Market Insights (FMI). The overall sodium lactate sales are expected to reach US$ 368.3 Mn by 2031, growing at a CA...
- 2022년 03월 10일
-
- ANANDA Scientific and NYU Grossman School of Medicine Announce First Patient Enrolled in the Clinical Trial for Opioid Sparing in Participants with Radiculopathic Pain
- ANANDA Scientific Inc., a biotech pharmaceutical company, and NYU Grossman School of Medicine today announced that the first patient has been enrolled in a clinical trial evaluating Nantheia™ A1002N5S, an in...
- 2022년 03월 09일
-
- Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced ...
- 2022년 03월 08일
-
- Schneider Electric announces promising start of its Sustainability Impact program
- Schneider Electric, the leader in the digital transformation of energy management and automation, announced today the progress made on its Schneider Sustainability Impact (SSI) program at the end of Q4 2021,...
- 2022년 03월 08일
-
- GI Innovation Forms Co-representative System by Recruiting CEO Byung-Geon Rhee, Former CEO of GC Pharma and SCM Lifescience
- GI Innovation, a new innovative drug development company, announced on March 4th that it has recruited Chief Executive Officer (CEO) and Chairman, Byung-Geon Rhee, former CEO of GC Pharma, SCM Lifescience Co...
- 2022년 03월 07일
-
- Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today announced ...
- 2022년 03월 03일
-
- Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
- Takeda (TSE:4502/NYSE:TAK) today presented four abstracts including interim real-world data from the observational Phase 4 EMPOWER study of TAKHZYRO® (lanadelumab) as a treatment for people with Hereditary A...
- 2022년 03월 02일
-
- FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®
- Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food an...
- 2022년 03월 02일
-
- Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy
- Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochloride [H...
- 2022년 03월 02일
-
- Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
- Regulatory News: This press release features multimedia. View the full release here: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Eur...
- 2022년 02월 28일
-
- Oncocross Begins Phase I Clinical Trial of AI-Developed Drug for Sarcopenia
- Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular diseases including sarcopenia. Oncocross obtained Australia’s Thera...
- 2022년 02월 28일
-
- GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease
- GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, and the Wyss Center, a non-profit organization dedicated to acc...
- 2022년 02월 25일
-
- ASEAN Safety Sensors and Switches Market is estimated to be worth around USD 1.58 Bn in 2032: Future Market Insights
- The market for safety sensors and switches in ASEAN countries is likely to grow by more than 8%, yearly, in 2019. As depicted in a new research study of Future Market Insights (FMI), the adoption of safety s...
- 2022년 02월 25일
전시회
